Week 144 Results of a Phase II, Randomized, Multicenter Trial Assessing the Safety and Efficacy of Ocrelizumab in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS)

被引：0
|
作者：
Hauser, Stephen [1 ]
Li, David [2 ]
Calabresi, Peter [3 ]
O'Connor, Paul [4 ]
Bar-Or, Amit [5 ,6 ]
Barkhof, Frederik [7 ]
Sauter, Annette [8 ]
Leppert, David [9 ]
Masterman, Donna [8 ]
Tinbergen, Jeroen [8 ]
Kappos, Ludwig [10 ,11 ]
机构：
[1] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA
[2] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
[3] Johns Hopkins Univ, Baltimore, MD USA
[4] Univ Toronto, Dept Neurol, Toronto, ON, Canada
[5] McGill Univ, Montreal Neurol Inst & Hosp, Neuroimmunol Unit, Montreal, PQ, Canada
[6] McGill Univ, Montreal Neurol Inst & Hosp, Expt Therapeut Program, Montreal, PQ, Canada
[7] Vrije Univ Amsterdam, Med Ctr, Dept Radiol, Amsterdam, Netherlands
[8] F Hoffmann La Roche Ltd, Basel, Switzerland
[9] PDCN F Hoffmann La Roche, Basel, Switzerland
[10] Univ Basel Hosp, CH-4031 Basel, Switzerland
[11] Univ Basel Hosp, Dept Biomed, CH-4031 Basel, Switzerland
来源：
NEUROLOGY | 2013年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
S31004
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Safety and Efficacy of Fingolimod in Iranian Patients with Relapsing-remitting Multiple Sclerosis
    Yavari, Fatemeh
    Oliazadeh, Pardis
    Radfar, Meisam
    Foroughipour, Mohsen
    Nikkhah, Karim
    Bakavoli, Alireza Heidari
    Saeidi, Morteza
    BASIC AND CLINICAL NEUROSCIENCE, 2021, 12 (02) : 233 - 242
  • [22] A retrospective chart review in patients with relapsing-remitting multiple sclerosis (RRMS)
    Cursiefen, S.
    Kanter, I.
    Niemczyk, G.
    Schicklmaier, P.
    Wernsdoerfer, C.
    Schwab, S.
    Maeurer, M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2008, 15 : 142 - 142
  • [23] Switching from natalizumab to ocrelizumab in patients with relapsing-remitting multiple sclerosis
    Van Lierop, Z.
    Toorop, A.
    Willemse, E.
    Strijbis, E.
    Kalkers, N.
    Moraal, B.
    Barkhof, F.
    Teunissen, C.
    Killestein, J.
    Van Kempen, Z.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 310 - 311
  • [24] Daclizumab phase I/II trial in relapsing-remitting multiple sclerosis: MRI and clinical results
    Rose, J.
    Burns, J.
    Bjorklund, J.
    Klein, J.
    Watt, H.
    Carlson, N.
    MULTIPLE SCLEROSIS, 2006, 12 : S105 - S105
  • [25] Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis A phase 2 study
    Sorensen, Per S.
    Lisby, Steen
    Grove, Richard
    Derosier, Frederick
    Shackelford, Steve
    Havrdova, Eva
    Drulovic, Jelena
    Filippi, Massimo
    NEUROLOGY, 2014, 82 (07) : 573 - 581
  • [26] Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS)
    Gold, Ralf
    Giovannoni, Gavin
    Phillips, J. Theodore
    Fox, Robert J.
    Zhang, Annie
    Meltzer, Leslie
    Kurukulasuriya, Nuwan C.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 (01) : 57 - 66
  • [27] Safety and efficacy of helminth treatment in relapsing-remitting multiple sclerosis: Results of the HINT 2 clinical trial
    Fleming, John
    Hernandez, Gianna
    Hartman, Leslie
    Maksimovic, Jane
    Nace, Sara
    Lawler, Benjamin
    Risa, Todd
    Cook, Thomas
    Agni, Rashmi
    Reichelderfer, Mark
    Luzzio, Christopher
    Rolak, Loren
    Field, Aaron
    Fabry, Zsuzsanna
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 (01) : 81 - 91
  • [28] Results from the CLARITY Study: a Phase III, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Oral Cladribine in Relapsing-Remitting Multiple Sclerosis (RRMS)
    Giovannoni, Gavin
    Comi, Giancarlo
    Cook, Stuart D.
    Rammohan, Kottil W.
    Rieckmann, Peter
    Sorensen, Per Soelberg
    Vermersch, Patrick
    Chang, Peter
    Hamlett, Anthony
    Musch, Bruno
    Greenberg, Steven J.
    NEUROLOGY, 2009, 73 (04) : 330 - 330
  • [29] Long-term efficacy and safety of ponesimod: results from randomized phase ii core and extension studies in relapsing-remitting multiple sclerosis
    Freedman, M.
    Pozzilli, C.
    Havrdova, E. Kubala
    Coyle, P.
    Lemle, A.
    Burcklen, M.
    Larbalestier, A.
    Hennessy, B.
    Scherz, T.
    Vaclavkova, A.
    Olsson, T.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 222 - 222
  • [30] Efficacy and Safety of Oral Therapies for Relapsing-Remitting Multiple Sclerosis
    Paolicelli, Damiano
    Manni, Alessia
    Iaffaldano, Antonio
    Trojano, Maria
    CNS DRUGS, 2020, 34 (01) : 65 - 92
12345